Title
Serological response to COVID-19 vaccination in IBD patients receiving biologics

Authors
Serre-Yu Wong, The Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
Rebekah Dixon, The Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
Vicky Martinez Pazos, The Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
ICARUS-IBD Working Group**
Sacha Gnajatic, The Precision Immunology Institute, Tisch Cancer Institute, Division of Hematology/Oncology, Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York
Jean-Frederic Colombel*, The Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
Ken Cadwell*, Skirball Institute of Biomolecular Medicine, Department of Microbiology, Division of Gastroenterology and Hepatology, Department of Medicine, New York University School of Medicine, New York, New York

*These authors share co-senior authorship.

Barcessat, Natalia Herrera, Jack Satsangi, Kenji Watanabe, Séverine Vermeire, Flavio Steinwurz, Mark Silverberg, David T. Rubin, Giulia Roda, Walter Reinisch, Siew Chien Ng, James Lindsay, Jonas Halfvarson, Matthieu Allez, Vineet Ahuja, Maria Abreu

Corresponding author
Serre-Yu Wong, One Gustave L. Levy Place, Box 1069, New York, New York 10029, Serre-Yu.Wong@mountsinai.org, 212-241-3179

Conflict of Interest
Sacha Gnjatic: Research grants from Bristol-Myers Squibb, Genentech, Immune Design, Agenus, Janssen R&D, Pfizer, Takeda, and Regeneron; advisory roles for Merck, Neon Therapeutics and OncoMed. Jean-Frederic Colombel: Research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Bristol-Myers Squibb Company, Ferring Pharmaceuticals, Shire, Takeda and Tillots; has received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Gilead, Iterative Scopes, Ipsen, Immunic, Imtbio, Inotrem, Janssen Pharmaceuticals, Landos, LimmaTech Biologics AG, Medimmune, Merck, Novartis, OMass, Otsuka, Pfizer, Shire, Takeda, Tigenix, Viela bio; and holding stock options in Intestinal Biotech Development. Ken Cadwell: Research funding from Pfizer, Takeda, and Abbvie; consulted for or received an honorarium from Puretech Health, Genentech, and Abbvie; and holds U.S. patent 10,722,600 and provisional patent 62/935,035. The remaining authors disclose no conflicts.

Funding
This work was supported by the Helmsley Charitable Trust and Cure for IBD. This effort was supported by the Serological Sciences Network (SeroNet) of the National Cancer Institute, National Institutes of Health, under Contract No. 75N91019D00024, Task Order No. 75N91020F00003. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the U.S. Government. Sacha Gnjatic was supported by NIH grants CA224319 and DK124165. This work was supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai. Supported by grant UL1TR001433 from the National Center for Advancing Translational Sciences, National Institutes of Health. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Authorship Contributions

Serre-Yu Wong (Conceptualization: Lead; Data curation: Equal; Formal analysis: Equal; Funding acquisition: Lead; Investigation: Equal; Methodology: Equal; Project administration: Equal; Supervision: Lead; Visualization: Lead; Writing – original draft: Lead; Writing – review & editing: Equal). Rebekah Dixon (Conceptualization: Equal; Data curation: Equal; Investigation: Equal; Methodology: Equal; Project administration: Equal; Writing – review & editing: Equal). Vicky Martinez Pazos (Investigation: Equal; Methodology: Equal; Lead; Writing – review & editing: Supporting). Sacha Gnjatic (Conceptualization: equal; Data curation: Equal; Formal analysis: Equal; Methodology: Equal; Visualization: Equal; Writing – review & editing: Equal). Jean-Frederic Colombel (Conceptualization: Equal; Formal analysis: Equal; Funding acquisition: Equal; Methodology: Supporting; Writing – review & editing: Equal). Ken Cadwell
(Conceptualization: Equal; Formal analysis: Equal; Funding acquisition: Equal; Methodology: Equal; Writing – review & editing: Equal).

Acknowledgements
The authors wish to thank The Mount Sinai Therapeutic Infusion Center team and Yamilka Costanza for their contributions to patient recruitment; James Freeman, Justin Conklin, Neil Birmingham, Don Chalfin, Ross Molinaro, Kim Wilson, and Siemens for their support for serological testing; Gustavo-Martinez-Delgado and Louis Cohen for laboratory support; Miriam Merad for valuable input on the study design.
Abstract

Objective The impact of medications on COVID-19 vaccine efficacy in IBD patients is unknown, as patients with immunosuppressed states and/or treated with immunosuppressants were excluded from vaccine trials. To address this, we evaluated serological responses to COVID-19 vaccination with the SARS-CoV-2 spike (S) mRNA BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (NIH-Moderna) vaccines in IBD patients enrolled in an ongoing SARS-CoV-2 sero-survey at the Icahn School of Medicine at Mount Sinai in New York City.

Design We obtained sera from 48 patients who had undergone vaccination with one or two vaccine doses. Sera were tested for SARS-CoV-2 anti-RBD total immunoglobulins and IgG (Siemens COV2T and sCOVG assays), anti-Spike IgG (in-house ELISA), and anti-nucleocapsid antibodies (Roche).

Results All IBD patients (15/15) who completed two-dose vaccine schedules achieved seroconversion to high levels. Two IBD patients with history of COVID-19 infections and who were seropositive at baseline seroconverted to high levels after the first dose. Concurrent biologic use was 85% (41/48), including 33% of patients (16) on TNF antagonist monotherapy, 42% (17) on vedolizumab monotherapy, 6% (3) on vedolizumab combination therapy with thiopurine, and 8% (4) ustekinumab; 1 patient was receiving guselkumab for psoriasis. Three patients (6%) were on oral steroids at the time of vaccination.

Conclusion IBD patients receiving biologics can seroconvert with robust serological responses after complete Pfizer-BioNTech and NIH-Moderna COVID-19 vaccination. In IBD-patients with previous SARS-CoV-2 seroconversion, a single dose of either vaccine can induce high index values, mirroring findings from the general population.
Introduction

Inflammatory bowel disease (IBD) patients with Crohn’s disease (CD) and ulcerative colitis (UC), have been considered at increased risk of severe COVID-19 since they are often treated with immunosuppressive medications. Medications such as steroids and thiopurines particularly in combination therapy with TNF antagonists, though not TNF antagonist monotherapy, have been shown to contribute to the risk of severe COVID-19 in IBD patients\textsuperscript{3,4}. Expert consensus advocates that IBD patients should be vaccinated against SARS-CoV-2\textsuperscript{5}. Although data from other vaccine-preventable illnesses suggest attenuated responses in patients receiving TNF antagonists and immunomodulators\textsuperscript{6}, the impact of medications on COVID-19 vaccine efficacy in IBD patients is unknown, as patients with immunosuppressed states and/or treated with immunosuppressants were excluded from vaccine trials. To address this, we evaluated serological responses to COVID-19 vaccination with the SARS-CoV-2 spike (S) mRNA BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (NIH-Moderna) vaccines in IBD patients enrolled in an ongoing SARS-CoV-2 sero-survey at our institution\textsuperscript{7}.

Methods

Specimens were collected at routine infusion and outpatient clinic visits as part of an ongoing longitudinal SARS-CoV-2 sero-surveillance study of IBD patients at the Icahn School of Medicine at Mount Sinai. Patients were asked to report if they had at least one vaccination appointment between the first date of vaccine distribution in New York City on December 14, 2020, and February 12, 2021. Control cohorts included vaccinated (1) healthcare workers (HCW) without IBD who had completed both doses of either vaccine and (2) volunteers (PICR cohort) without IBD who underwent serial blood draws after vaccination. The study protocols are approved by the Icahn School of Medicine at Mount Sinai Institutional Review Board.
IBD patient and HCW sera were analyzed using (1) the emergency use authorization (EUA) Siemens Healthineers COV2T and sCOVG assays which test for total immunoglobulins (Igs) and IgG, respectively, to the receptor binding domain (RBD) of the SARS-CoV-2 S protein and (2) the EUA Roche assay for antibodies to nucleocapsid protein. An in-house ELISA testing for IgG against full-length S protein was performed for IBD patients and both HCW and PICR controls. See Supplementary Methods for additional details.

Results

Forty-eight IBD patients were included, including 23 CD and 25 UC patients (Supplementary Table 1). Most patients were receiving biologics at the time of vaccination (41 patients, 85%), including 16 (33%) TNF antagonist monotherapy, 17 (42%) vedolizumab monotherapy, 3 (6%) vedolizumab combination therapy with thiopurine, and 4 (8%) ustekinumab; 1 patient was receiving guselkumab for psoriasis. Three patients (6%) were on oral steroids at the time of vaccination. Five (10%) patients were on no medications. Controls, including 14 vaccinated HCWs (mean age 35.2, 50% female) and 29 vaccinated subjects in the PICR cohort (mean age 31.5, 39% female), were younger than the IBD cohort (p = 0.028 and p < 0.0001, respectively).

Participants received either Pfizer-BioNTech (IBD n = 23, HCW n = 11, PICR n = 20) or NIH-Moderna (IBD n = 25, HCW n = 3, PICR n = 9) vaccines. Thirty-three IBD patients had completed only the first dose, and 15 patients had completed both doses. All HCWs and 15 (52%) PICR controls completed both doses.

Three IBD patients (2 with previous COVID-19 and 1 with confirmed mild COVID-19 between dose 1 and 2) and one HCW (6% versus 7%) reported laboratory-confirmed COVID-19 infection by nasopharyngeal PCR or SARS-CoV-2 antibody testing after recovery. All other samples tested negative for anti-nucleocapsid antibodies. Pre-vaccine baseline samples obtained from
19 patients without a history of COVID-19 showed absence of SARS-CoV-2-specific antibodies by all assays, and 1 patient with prior COVID-19 had anti-RBD and anti-nuclecapsid antibodies at baseline. We were unable to collect baseline samples from the remaining patients due to enrollment after vaccination. Among 14 HCW controls, 1 (7%) had baseline sera drawn, and among PICR controls, 5 (17%) had baseline IgG reactivity to Spike protein due to prior infection.

All IBD patients (n = 15) who completed two-dose vaccine schedules seroconverted and achieved index levels which would have been high enough to qualify for convalescent plasma donation (ref) (Figure 1). Percent seroconversion by week is also shown. Two IBD patients with prior infection achieved high index values after a single vaccine dose, well above values achieved from natural SARS-CoV-2 infection (Figure 1a). Analysis of anti-S IgG levels of IBD patients compared to the PICR and HCW cohorts showed similar titers at most time points with a possible lag at 2-3 weeks post the first vaccine dose (p = 0.011) (Figure 1c).

Of the 15 patients who completed both COVID-19 vaccine doses, 5 were receiving TNF antagonist monotherapy, 9 vedolizumab monotherapy, and 2 no medications. Analyses of the effects of anti-TNF and vedolizumab monotherapy in these patients revealed no significant differences in index values for anti-RBD IgG. However, vedolizumab was associated with lower COV2T anti-RBD total Ig (0.02) and anti-S IgG (p = 0.0043) levels (Supplementary Figure 1).

**Discussion**

We report a 100% seroconversion rate to complete Pfizer-BioNTech and NIH-Moderna COVID-19 vaccination in IBD patients on biologic monotherapy with robust serological responses. In IBD-patients with previous SARS-CoV-2 seroconversion, a single dose of either vaccine can induce high index values, mirroring findings from a recent HCW study. We also found an association of lower antibody levels in patients with vedolizumab. This finding is of unclear
clinical significance and warrants further investigation, as this result could have been affected by timing, vaccine, or clinical characteristics such as age.

This is the first data of serological responses to COVID-19 vaccines in IBD patients with detailed analysis of antibodies to both nucleocapsid and RBD/spike proteins. The study is limited to our single center experience. In addition, there were differences in time to blood collections between IBD patients and controls. Despite these limitations, our results support the consensus recommendation for IBD patients to receive COVID-19 vaccines when available\textsuperscript{5}. Our study also highlights the need for future studies to assess earlier time points and longitudinal studies to assess full immune responses, including cell-mediated responses, effects of other medications, and clinical efficacy of different vaccine types to guide optimal dosing regimens and/or vaccine choice in IBD patients.
References


Author names in bold designate shared co-first authorship.
Figure 1. Antibody response to SARS-CoV-2 immunization in IBD patients compared with healthcare worker controls. (A) Siemens COV2T and sCOVG testing for total Ig and IgG against SARS-CoV-2 RBD. Thresholds for positive tests and maximum index value for COV2T is shown by dotted lines as indicated. Percent seroconversion over time since first vaccine dose in IBD patients is shown in the table. (C) Anti-Spike IgG results comparing IBD to PICR/HCW cohorts over time.
Figure 1. Antibody response to SARS-CoV-2 immunization in IBD patients compared with healthcare worker controls.

A

Anti-RBD Total Ig

Days after first vaccine dose

IBD vaccinated - 1 dose
IBD vaccinated - 2 doses
IBD with prior infection vaccinated - 1 dose
Non-vaccinated IBD with prior infection
Non-IBD HCW vaccinated - 2 doses

Days after first vaccine dose

Anti-RBD IgG

Threshold for positive test

Convalescent Plasma Donor Cutoff

Mean rank of PICR Cohort/HCW

Mean rank of IBD Cohort

Mean rank diff.

Mann-Whitney U

q value

Days after 1st vaccine dose
% seroconversion (seroconverted/tested)
Day 1-7
0% (0/4)
Day 8-15
46% (6/13)
Day 16-21
67% (6/9)
Day 22-28
71% (5/7)
Day 27-60
100% (15/15)
(Day 2-36 after 2nd dose)

B

PICR/HCW vs IBD cohorts

Anti-Spike IgG Titer

Time point

Baseline (pre vaccine)
1-4 days post 1st vaccine
1-2 weeks post 1st vaccine
2-3 weeks post 1st vaccine
1 week post 2nd vaccine
2 weeks post 2nd vaccine

*